BioMarin Pharmaceuticals
BMRN
554 hedge funds and large institutions have $12.7B invested in BioMarin Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 198 increasing their positions, 199 reducing their positions, and 86 closing their positions.
36% more call options, than puts
Call options by funds: $152M | Put options by funds: $112M
1% less repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 199
1% less first-time investments, than exits
New positions opened: 85 | Existing positions closed: 86
1% less funds holding
Funds holding: 560 → 554 (-6)
2.57% less ownership
Funds ownership: 97.34% → 94.77% (-2.6%)
17% less capital invested
Capital invested by funds: $15.2B → $12.7B (-$2.54B)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$225M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$95.4M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$67.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$54M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$45.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$211M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$90.6M |
| 3 |
Barclays
London,
United Kingdom
|
-$69.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$68M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$62.2M |
BMRN Hedge Fund Activity: Q3 2024 in Review
554 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2024, worth a combined $12.7B — down 17% from $15.2B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of BMRN and 85 opened new positions — a net loss of 1 holder — while 199 trimmed existing stakes and 198 added.
The largest buyer was Viking Global Investors, adding an estimated $225M. The largest seller was Avoro Capital Advisors, cutting an estimated $211M.
- 554 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2024, down from 560 in Q2 2024.
- Funds reported $12.7B of BioMarin Pharmaceuticals stock for Q3 2024, down 17% quarter-over-quarter.
- 85 funds opened new BioMarin Pharmaceuticals positions in Q3 2024 and 86 closed out, a net change of -1 holder.
- The largest BioMarin Pharmaceuticals buyer in Q3 2024 was Viking Global Investors, an estimated $225M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2024 was Avoro Capital Advisors, an estimated $211M sold.
Based on aggregated 13F filings for Q3 2024.